Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | Zendy

SeockAh Im | Zendy; YenShen Lu | Zendy; Aditya Bardia | Zendy; Nadia Harbeck | Zendy; Marco Colleoni | Zendy; Fábio Franke | Zendy; Louis W.C. Chow | Zendy; Joohyuk Sohn | Zendy; Keun-Seok Lee | Zendy; Saul CamposGómez | Zendy; Rafael Villanueva-Vázquez | Zendy; Kyung-Hae Jung | Zendy; Arunava Chakravartty | Zendy; Gareth Hughes | Zendy; Ioannis Gounaris | Zendy; Karen Rodriguez-Lorenc | Zendy; Tetiana Taran | Zendy; Sara A. Hurvitz | Zendy; Debu Tripathy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

Author(s) -

SeockAh Im,

YenShen Lu,

Aditya Bardia,

Nadia Harbeck,

Marco Colleoni,

Fábio Franke,

Louis W.C. Chow,

Joohyuk Sohn,

Keun-Seok Lee,

Saul CamposGómez,

Rafael Villanueva-Vázquez,

Kyung-Hae Jung,

Arunava Chakravartty,

Gareth Hughes,

Ioannis Gounaris,

Karen Rodriguez-Lorenc,

Tetiana Taran,

Sara A. Hurvitz,

Debu Tripathy

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1903765

Subject(s) - medicine , hazard ratio , tamoxifen , breast cancer , oncology , aromatase inhibitor , interim analysis , population , placebo , palbociclib , clinical endpoint , cancer , gynecology , confidence interval , randomized controlled trial , metastatic breast cancer , pathology , alternative medicine , environmental health

An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research